medigraphic.com
ISSN 1561-2937 (Print)

2020, Number 3

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2020; 26 (3)

Critical path in pediatric patient cardiac follow-up with active cancer disease

González MAE

Language: Spanish
References: 39
Page: 1-9
PDF size: 299.73 Kb.


ABSTRACT

The conception of curative therapies applied to children with cancer presents considerable achievements. Cardio - oncology is a new horizontal discipline dedicated to the diagnosis and treatment of cardiovascular diseases induced by cancer treatment; however, questions arise related to the strategies to be developed in the pediatric patient during the time of tumor activity regardless of therapeutic reception.
Pediatric cardio - oncology is particularized with respect to its counterpart in the adult through differences related to the onco – hematological entities it faces, the systemic and cardiovascular co – morbidities identified, the drug approaches applied, the characterization of the myocardium in the child and the therapeutic responses of the organism. The adoption of follow-up strategies for pediatric patients in tumor activity requires the multidisciplinary approach dedicated to cardiovascular monitoring from the pre – treatment stage.
The analysis of each details and peculiarities inherent to the aforementioned monitoring modality establishes its critical route that is based on systematic prevention, risk stratification in conjunction with the early diagnosis of cardiotoxicity and the protective medication of the cardiovascular system.


REFERENCES

  1. López-Fernández T, Martín García A, Santaballa Beltrán A, Montero LA, García Sanz R, Mazón Ramos P. Cardio-Onco-Hematología en la práctica clínica. Documento de consenso y recomendaciones. Rev Esp Cardiol. 2017; 70:474-86.

  2. Miller KD, Siegel RL, Lin CC. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2016; 66:271-89.

  3. Jain D, Russell RR, Schwartz RG, Panjrath GS, Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep. 2017; 19:36-9.

  4. Xinqiang H, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. npj Precision Oncology. 2017; 31:1-11.

  5. Herrmann J, Lerman A, Sandhu NP. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014; 89:1287–1306.

  6. Nhola LF, Villarraga HR. Rationale for Cardio-Oncology Units. Rev Esp Cardiol. 2017; 70:583-89.

  7. Ryan TD, Nagarajan R, Godow J. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. Curr. Treat. Options in Oncol. 2019; 20: 56-63.

  8. Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovascular Research. 2019; 115: 922-34.

  9. Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Leahy AB, Sack L. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children’s Oncology Group. J Clin Oncol. 2019; 37:12-21.

  10. Lipshultz SE, Adams MJ, Colan SD. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013; 128:1927-95.

  11. Ganame J, Claus P, Uyttebroeck A. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr. 2007; 20:1351-8.

  12. Armenian SH, Lacchetti C, Barac A. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017; 35:893-1.

  13. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007; 8:1039-58.

  14. Bloom MW, Hamo CE, Cardinale D. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016; 9:e002661.

  15. Van Dalen EC, Van der Pal HJ, Kremer LC. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2016; 3:CD005008.

  16. Zamorano JL, Lancellotti P, Rodriguez Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37:2768-801

  17. Armenian SH, Hudson MM, Chen MH. Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovasc Disord. 2016; 16:187-9.

  18. Planas JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from American Society of Echocardiography and the European Association of Cardiovascular imaging. European Heart Journal-Cardiovascular Imaging. 2014; 15:1063-93.

  19. Bossi G, Lanzarini L, Laudisa ML, Klersy C, Raisaro A, Aric M. Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines. Medical and Pediatric Oncology. 2001; 36:593-600.

  20. Chang HM, Moudgil R, Scarabelli. Cardiovascular Complications of Cancer Therapy Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017; 70:2536-51.

  21. Kenigsberg B, Wellstein A, Barac A. Left Ventricular Dysfunction in Cancer Treatment. Is it Relevant ? J Am Coll Cardiol. 2018; 6: 87-95.

  22. Ponikowski P, Voors AA, Anker SD. Guidelines for the diagnosis and treatment of acute and chronic heart failure European Heart Journal. 2016; 37, 2129-2200.

  23. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978; 88:168-75.

  24. Cardinale D, Colombo A, Bacchiani G. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131:1981-1988.

  25. Gibson TM, Mostoufi-Moab S, Stratton KL, Barnea D, Chow EJ, Donaldson SS, Howell RM et al. Temporal patterns in the risk of chronic health conditions among survivors of childhood cancer diagnosed 1970-1999: a report from the Childhood Cancer Survivor Study. Lancet Oncol. 2018; 19:1590-1601.

  26. Tilemann LM, Heckmann MB, Katus HA, Lehmann LH, Muller OJ. Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clinical Research in Cardiology. 2018; 107:271-80.

  27. Teskle AJ, Linschoten M, Kamphuis JAM. Cardio-oncology: an overview on outpatient management and future developments. Neth Heart J. 2018; 26:521-32.

  28. Fisher RS, Rausch JR, Ferrante AC. Trajectories of health behaviors across early childhood cancer survivorship. Psychooncology. 2019; 28:68-75.

  29. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010; 102:14-25.

  30. Chung WB, Youn HJ. Pathophisiology and preventive strategies of antracycline-induced cardiotoxicity. Korean J Intern Med. 2016; 31:625-33.

  31. Vincent DT, Ibrahim YF, Espey MG, Suzuki YJ, The role of antioxidants in the era of cardio-oncology. Cancer Chemother Pharmacol. 2013; 72:1157-68.

  32. Lipshultz SE, Sambatakos P, Maguire M, Karnik R. Cardiotoxicity and cardioprotection in childhood cancer. Acta Haematol. 2014; 132:391-9.

  33. Schwartz CL, Wexler LH, Krailo MD. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016; 63:54-61.

  34. Stefani L, Pedrizzetti G, Galanti G. Clinical Application of 2D speckle tracking strain for assessing cardiotoxicity in Oncology. J Funct Morphol Kinesiol. 2016; 1:343–54.

  35. Tadic M, Genger M, Cuspidi C, Belyavskiy E. Phasic left atrial function in cancer patients before initiation of anticancer therapy. J Clin Med. 2019; 8:421–8.

  36. Jiménez-Cotes EA, Meyer-Martínez WS, Gallego-González D. Biomarcadores en la detección temprana de Cardiotoxicidad Inducida por quimioterapia; estado actual. Arch Med (Manizales). 2015; 15:126-37.

  37. Jarfelt M, Kujacic V, Holmgren D, Bjarnason R, Lannering B. Exercise echocardi¬ography reveals sub-clinical cardiac dysfunction in young adult survivors of child¬hood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007; 49:835-40.

  38. Sheng CC, Amiri-Kordestani L, Palmby T, Force T. 21ST. century cardio-oncology. Identifying cardiac safety signals in the era of personalized medicine. J Am Coll Cardiol. Basic Trans Science. 2016; 1:386-98.

  39. Kostakou PM, Kouris NT, Kostopoulos VS, Damaskos DS, Olympios CD. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2019; 24:91–100.




2020     |     www.medigraphic.com